Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.01
-0.0100-0.06%
Post-market: 17.010.00000.00%19:30 EDT
Volume:426.80K
Turnover:7.26M
Market Cap:881.60M
PE:16.28
High:17.06
Open:17.06
Low:17.00
Close:17.02
52wk High:21.03
52wk Low:13.08
Shares:51.83M
Float Shares:25.86M
Volume Ratio:1.63
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.05
EPS(LYR):2.06
ROE:20.91%
ROA:1.33%
PB:3.04
PE(LYR):8.26

Loading ...

Theravance Biopharma Inc : H.c. Wainwright Cuts to Neutral Rating

THOMSON REUTERS
·
Jul 07

Zymeworks Said to Near $929 Million Deal for Theravance - Bloomberg News

Reuters
·
Jul 03

Major Insider Move Rocks Theravance Biopharma Shares

TIPRANKS
·
Jul 02

Theravance Biopharma 10% Owner Eli Samaha Sells 336,697 Common Shares Worth $5.78 Million

Reuters
·
Jul 02

PRESS Digest-canada - June 30

Reuters
·
Jun 30

Theravance Biopharma Cut to Neutral from Buy by BTIG

Dow Jones
·
Jun 29

Zymeworks’ TBPH Acquisition Seen as Cash-Flow Accretive, Supports Buy Rating and Unchanged $34 Price Target

TIPRANKS
·
Jun 29

BTIG Downgrades Theravance Biopharma to Neutral From Buy

MT Newswires Live
·
Jun 29

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)

TIPRANKS
·
Jun 29

Theravance Biopharma downgraded to Neutral from Buy at BTIG

TIPRANKS
·
Jun 29

Theravance Biopharma Inc : Btig Cuts to Neutral from Buy

THOMSON REUTERS
·
Jun 29

Zymeworks Down 6.1%

THOMSON REUTERS
·
Jun 29

Theravance Biopharma Inc : Jonestrading Cuts to Hold Rating

THOMSON REUTERS
·
Jun 29

Zymeworks Posts Investor Presentation on Planned Theravance Biopharma Acquisition for Yupelri Cash Flows

Reuters
·
Jun 29

Deals of the Day-mergers and Acquisitions

Reuters
·
Jun 29

Why This Biotech Stock is Falling After a $929 Million Buyout Lifeline

Dow Jones
·
Jun 29

Theravance Biopharma: Co to Pay $32.5 Mln Termination Fee to Zymeworks, if Deal Terminated Under Certain Circumstances

THOMSON REUTERS
·
Jun 29

Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash

TIPRANKS
·
Jun 29

Theravance Biopharma Shares Fall 3.3% Premarket; Co to be Acquired by Zymeworks for $17 Per Share in Cash Plus a Contingent Value Right

THOMSON REUTERS
·
Jun 29

Zymeworks to Acquire Theravance Biopharma for USD 17 Per Share in USD 929 Million Deal

Reuters
·
Jun 29